Clinical Trials on Prostate Cancer (CRPC)

Total 52533 results

Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

Prostate Cancer | Prostate Neoplasms | Castration Resistant Prostate Cancer (CRPC)

Japan
Pharmicell Co., Ltd.

Terminated

Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC)

Castration Resistant Prostate Cancer, CRPC

Korea, Republic of
Effector Therapeutics

Completed

An Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)

Castrate-resistant Prostate Cancer (CRPC)

United States
Bellicum Pharmaceuticals
M.D. Anderson Cancer Center; The University of Texas Health Science Center,... and other collaborators

Completed

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Castrate Resistant Prostate Cancer (CRPC)

United States
Innocrin Pharmaceutical

Completed

A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Castration-resistant Prostate Cancer | CRPC

United States, Greece, Switzerland, United Kingdom
Innocrin Pharmaceutical

Completed

A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Castration-resistant Prostate Cancer | CRPC

United States
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer (ODENZA)

Metastatic Castrate-resistant Prostate (CRPC) Cancer

France
Translational Research Center for Medical Innovation...

Completed

A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC (DELC)

Castration Resistant Prostate Cancer (CRPC)
Tiltan Pharma Ltd.

Unknown

Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC) (TLH-202)

Metastatic Castration Resistant Prostate Cancer (CRPC)

Israel
Sidney Kimmel Comprehensive Cancer Center at Johns...

Withdrawn

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer (Radium-223)

Prostate Cancer | Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)

United States
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Castration Resistant Prostate Cancer (CRPC) | Pharmacokinetics of MDV3100

South Africa
BIND Therapeutics

Completed

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | CRPC

United States
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects

Healthy Subjects | Relative Bioavailability | Castration Resistant Prostate Cancer (CRPC) | MDV3100

Germany
Sandy Srinivas
Wyeth is now a wholly owned subsidiary of Pfizer; American Society of Clinical... and other collaborators

Terminated

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

Prostatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate Cancer

United States
Stanford University

Terminated

Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

Prostatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate Cancer

United States
Bayer

Completed

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). (PHENIX)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States
Promontory Therapeutics Inc.

Active, not recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Urogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Advanced Solid Tumors | mCRPC | Metastatic Castrate-resistant Prostate Cancer | CRPC | PT-112

United States, France
FutureChem

Recruiting

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2 (LUCIDA_2)

Metastatic Castration-resistant Prostate Cancer, mCRPC

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
University of Texas Southwestern Medical Center

Completed

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

mCRPC | Metastatic Castrate-resistant Prostate Cancer

United States
Constellation Pharmaceuticals

Active, not recruiting

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
GenesisCare USA
Dendreon

Completed

A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T

Castrate Refractory Metastatic Prostate Cancer (mCRPC)

United States
Avionco LLC

Completed

Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Russian Federation
UNC Lineberger Comprehensive Cancer Center

Withdrawn

Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

Castration-Resistant Prostate Cancer (CRPC)

United States, Moldova, Republic of, South Africa
Bayer

Completed

EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo) (EPIX)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC)

China
Suzhou Kintor Pharmaceutical Inc,

Completed

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

United States
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Completed

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Progenics Pharmaceuticals, Inc.

Active, not recruiting

Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate | Prostatic Neoplasm | Progressive mCRPC

United States, Canada
Centre Francois Baclesse
National Cancer Institute, France

Completed

Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer (COG-PRO)

Metastatic Castration-resistant Prostate Cancer (CRPCa)

France
BeiGene

Terminated

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Homologous Recombination Deficiency (HRD)

United States, Australia, Puerto Rico, Spain
Pengyuan Liu

Recruiting

Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (CRPC)

China
Inmune Bio, Inc.

Recruiting

Study of INKmune in Patients With mCRPC (CaRe Prostate) (CaRe)

Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

United States
The First Affiliated Hospital of Xiamen University

Recruiting

Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer, mCRPC

China
University of Pennsylvania
Prostate Cancer Foundation

Recruiting

TmPSMA-02 in mCRPC

Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

United States
Peter MacCallum Cancer Centre, Australia

Recruiting

Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer (AlphaBet)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

Australia
British Columbia Cancer Agency

Recruiting

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA (PROTRACT)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Canada
AstraZeneca

Completed

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Advanced Accelerator Applications

No longer available

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

Metastatic Castration-resistant Prostate Cancer (mCRPC)
Suzhou Kintor Pharmaceutical Inc,

Completed

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Metastatic Castrate Resistant Prostate Cancer (mCRPC)

United States
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer (mCRPC)

China
Dendreon

Not yet recruiting

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T (ProvONE)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals

Recruiting

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Spain, France
Bayer

Recruiting

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Hong Kong, Spain, Taiwan, Australia, Turkey, France, Germany, Hungary, United Kingdom, Singapore, Korea, Republic of, Czechia, Italy, Finland, Israel, Austria, Lithuania, Poland, Russian Federation
Peter MacCallum Cancer Centre, Australia

Suspended

Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer (REPAIR)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Australia
Istituto Scientifico Romagnolo per lo Studio e...

Terminated

The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA) (WB-LuPSMA)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Italy
Karolinska Institutet
The Swedish Research Council; AstraZeneca; Janssen Pharmaceutica N.V., Belgium; Kom Op Tegen Kanker and other collaborators

Recruiting

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (ProBio)

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Sweden, Belgium, Switzerland, Norway
Celcuity Inc

Recruiting

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Genital Diseases, Male | Prostatic Disease | mCRPC (Metastatic Castration-resistant Prostate Cancer) | Urogenital Diseases, Male

United States, France, Spain, United Kingdom
SL VAXiGEN

Recruiting

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Korea, Republic of

Clinical Trials on Prostate Cancer (CRPC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations